This is my third Rhythm (NASDAQ: RYTM ) article, following 06/2025's "Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects." In Excellent Prospects , I rated Rhythm as a "Buy." It has since enjoyed a tasty ~52% bump. In this article, I will assess its forward prospectsWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha artic ...